Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.

首页 > 成果 > 详情

认领

导出

下载 Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Wang, Zhongtai;Zhang, Hui*;Zhou, Chunhua;Long, Xiaoyan;Guan, Rui;...

通讯作者：

Zhang, Hui;Yang, Nong

作者机构：

[Zhang, Hui; Zhou, Chunhua; Long, Xiaoyan; Guan, Rui; Yang, Nong; Wang, Zhongtai; Zhang, Yongchang] Cent S Univ, Dept Med Oncol, Lung Canc & Gastrointestinal Unit, Hunan Canc Hosp,Affiliated Canc Hosp,Xiangya Sch, Changsha, Hunan, Peoples R China.

[Zhang, Hui; Wang, Zhongtai] Univ South China, Grad Sch, Hengyang, Hunan, Peoples R China.

[Zhang, H; Zhang, Yongchang] Hunan Canc Hosp, Dept Med Oncol, Lung Canc & Gastrointestinal Unit, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Hunan, Peoples R China.

通讯机构：

[Zhang, H; Yang, N] H

Hunan Canc Hosp, Dept Med Oncol, Lung Canc & Gastrointestinal Unit, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Hunan, Peoples R China.

语种：

英文

关键词：

chemotherapy;different administration;non-small cell lung cancer;real-world study;recombinant human-endostatin

期刊：

Cancer Medicine

ISSN：

2045-7634

年：

2019

卷：

期：

页码：

1434-1441

DOI：

10.1002/cam4.2014

基金类别：

This work was partially supported by the National Natural Science Foundation of China (no. 81401902 and 81501992) and Hunan Natural Science Foundation of Hunan Province (2018JJ2238, 2017SK2134, and 2018RS3106).

机构署名：

本校为其他机构

摘要：

AIMS: This real-world study is conducted to evaluate the efficacy and safety of recombinant human endostatin (rh-endostatin) combined with chemotherapy as first-line treatment for non-driver genes mutation non-small cell lung cancer (NSCLC) patients, and establish evidence-based optimal regimen for rh-endostatin. PATIENTS AND METHODS: Using propensity score matching (cut-off: 0.01), 88 patients were eligible for our study, 34 of which received platinum-based chemotherapy alone (chemotherapy group), 54 patients received platinum-based chemotherapy plus rh-endostatin (rh-endostatin group). Among...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问